Cocrystal Pharma to Present at the 2017 Cantor Fitzgerald

ATLANTA, GA and BOTHELL, WA--(Marketwired - Sep 22, 2017) - Cocrystal Pharma, Inc. ( OTCQB : COCP ) today announced that Dr. Gary Wilcox and James Martin will be presenting a company overview at the Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 27, 2017 at 8:35am in the InterContinental New York Barclay Hotel.

About Cocrystal Pharma Cocrystal is a pharmaceutical company seeking to discover and develop novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. Cocrystal employs unique structure based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. These technologies, including our nucleoside chemistry expertise, are designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer. The company has identified promising, preclinical stage antiviral compounds for unmet medical needs including hepatitis, influenza and norovirus infections. Cocrystal has previously received strategic investments from Teva Pharmaceuticals, OPKO Health ( NASDAQ : OPK ), Brace Pharma Capital, LLC, and The Frost Group. For further information about Cocrystal, please refer to www.cocrystalpharma.com .

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements including our expectations regarding the research collaboration and the anticipated results. The words "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "could," "target," "potential," "is likely," "will," "expect" and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events including joint research collaboration. Important factors that could cause actual results to differ from those in the forward-looking statements include the uncertain results from any new research and the ability of scientists form each party to work smoothly. Further information on our risk factors is contained in our filings with the SEC, including our Form 10-K for the year ended December 31, 2016. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.